Transgenic mice overexpressing both amyloid β-protein and perlecan in pancreatic acinar cells

Histology and Histopathology

Volumn 19, Issue 3, 2004, Pages 845-852

  Fukuchi, Ken Ichiro ^a   Hart, M ^a,d   Yan, Z ^a   Hassell, J R ^b   Li, L ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

^c University of Alabama at Birmingham   (United States)

^d AUBURN UNIVERSITY   (United States)

Author keywords

Amyloid; Pancreas; Perlecan; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN; PERLECAN; THIOFLAVINE;

ACINAR CELL; AGING; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS BREEDING; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PANCREAS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENE; TRANSGENIC MOUSE;

AGING; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; ANIMALS; BLOTTING, WESTERN; BRAIN CHEMISTRY; CROSSES, GENETIC; HEPARAN SULFATE PROTEOGLYCANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; PANCREAS; TRANSGENES;

ANIMALIA; MUS MUSCULUS;

EID: 3042824912     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Ailles L., Kisilevsky R. and Young I.D. (1993). Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis. Lab. Invest. 69, 443-448.
2. Bayer T.A., Wirths O., Majtenyi K., Hartmann T., Multhaup G., Beyreuther K. and Czech C. (2001). Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol. 11, 1-11.
3. Castillo G.M., Ngo C., Cummings J., Wight T.N. and Snow A.D. (1997). Perlecan binds to the β-amyloid (AB) of Alzheimer's disease, accelerates Aβ fibril formation and maintains Aβ fibril stability. J. Neurochem. 69, 2452-2465.
4. Castillo G.M., Lukito W., Wight T.N. and Snow A.D. (1999). The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J. Neurochem. 72, 1681-1687.
5. Doege K., Chen X., Cornuet P.K. and Hassell J. (1997). Non-glycosaminoglycan bearing domains of perlecan and aggrecan influence the utilization of sites for heparan and chondroltin sulfate synthesis. Matrix Biol. 16, 211-221.
6. Dolan M., Horchar T., Rigatti B. and Hassell J.R. (1997). Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis. J. Biol. Chem. 272, 4316-4322.
7. Faulkner C.B., Simecka J.W., Davidson M.K., Davis J.K., Schoeb T.R., Lindsey J.R, and Everson M.P. (1995). Gene expression and production of tumor necrosis factor alpha, interleukin 1, interleukin 6, and gamma interferon in C3H/HeN and C57BL/6N mice in acute Mycoplasma pulmonis disease. Infect. Immun. 63, 4084-4090.
8. Fraser P.E., Nguyen J.T., Chin D.T. and Kirschner D.A. (1992). Effects of sulfate ions on Alzheimer β/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J. Neurochem. 59, 1531-1540.
9. Fukuchi K., Li L., Hart M. and Lindsey J.R. (2000). Accumulation of amyloid-β protein in exocrine glands of transgenic mice overexpressing a carboxyl terminal portion of amyloid protein precursor. Int. J. Exp. Pathol. 81, 231-239.
10. Fukuchi K., Ho L., Younkin S.G., Kunkel D.D., Ogburn C.E., Wegiel J., Wisniewski H.M., LeBoeuf R.C., Furlong C.E., Deeb S.S., Nochlin D., Sumi S.M. and Martin G.M. (1996). High levels of β -amyloid protein in peripheral blood do not cause cerebral β -amyloidosis in transgenic mice. Am. J. Pathol. 149, 219-227.
11. Greenberg S.G., Davies P., Schein J.D. and Binder L.I. (1992). Hydrofluoric acid-treated tau PHF proteins display the same biochemical proterties as normal tau. J. Biol. Chem. 263, 7948-7953.
12. Hart M., Li L., Tokunaga T., Lindsey J.R., Hassell J.R., Snow A.D. and Fukuchi K. (2001). Overproduction of perlecan core protein in cultured cells and transgenic mice. J. Pathol. 194, 262-269.
13. Kawarabayashl T., Shoji M., Sato M., Sasaki A., Ho L., Eckman C.B., Prada C.M., Younkin S.G., Kobayashi T., Tada N., Matsubara E., Iizuka T., Harigaya Y., Kasai K. and Hirai S. (1996). Accumulation of b-amyloid fibrils in pancreas of transgenic mice. Neuroblol. Aging 17, 215-222.
14. Klein W.L. (2002). Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41, 345-352.
15. Klein D.J., Brown D.M., Oegema T.R,. Brenchley P.E., Anderson J.C., Dickinson M.A., Horigan E.A. and Hassell F.R. (1988). Glomerular basement membrane proteoglycans are derived from a large precursor. J. Cell Biol. 106, 963-970.
16. McCubbin W.D., Kay C.M., Narindrasorasak S. and Kisilevsky R. (1988). Circular-dichroism studies on two murine serum amyloid A proteins. Biochem. J. 256, 775-783.
17. Selkoe D.J. (2002). Deciphering the genesis and fate of amyloid β-protein yields novel therapies for Alzheimers disease. J. Clin. Invest. 110, 1375-1381.
18. Snow A.D. and Wight T.N. (1989). Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol. Aging 10, 481-497.
19. Snow A.D., Sekiguchi R., Nochlin D., Kalaria R.N. and Kimata K. (1994). Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimers disease brain. Am. J. Pathol. 144, 337-347.
20. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J. and Selkoe D.J. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
21. Yamamoto T. and Hirano A. (1986). A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's neurofibrillary tangles. Neuropathol. Applied Neurobiol. 12, 3-9.